Company news

Neurotech International Ltd. news in 2022

Neurotech International Ltd.'s news releases, calls and decks from 2022, newest first.

View company

Disclosure Document

December 22, 2022

Commencement of Phase II/III ASD Clinical Trial

December 19, 2022

NTI Receives HREC/TGA Approval for Phase II/III ASD Trial

November 16, 2022

Neurotech Receives $1.2M R&D Tax Rebate

October 31, 2022

Reinstatement to Quotation

October 27, 2022

Neurotech Completes $9.0M Placement

October 27, 2022

Suspension From Official Quotation

October 26, 2022

20 Week Data Shows Significant Improvement For ASD Children

October 25, 2022

New Phase I/II Clinical Trial in Children with PANDAS/PANS

October 16, 2022

Executive Change

September 1, 2022

Q&A on NTI164 Breakthrough Clinical Trial Results in ASD

July 21, 2022

Reinstatement to Official Quotation

July 7, 2022

Breakthrough results with NTI164 in paediatric asd

July 7, 2022

Extension to Voluntary Suspension

July 7, 2022

Suspension from Official Quotation

July 6, 2022

Preclinical Success with Targeted Combination Therapies

June 9, 2022

Successful Landmark Study in Paediatric ASD

April 4, 2022

Notification regarding unquoted securities - NTI

March 10, 2022

Neurotech International: Proposed issue of securities - NTI

March 3, 2022

Appointment of Chief Executive Officer

March 2, 2022

Application for quotation of securities - NTI

January 24, 2022

Decks in 2022